Vendor Intelligence Report: Great Basin Bio Supply

Published 13 Jun 2026. 21-page investigative report on who is behind Great Basin Bio Supply: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 2 Finnrick lab tests, Great Basin Bio Supply has 2 passes and 0 fails, for an overall pass rate of 100%. That headline is real but extremely narrow: every current Finnrick result is BPC-157 from the launch batch. The BPC-157 signal is favorable on identity, purity, and endotoxin, while documented under-fill and vendor-submitted samples make the simple pass badge less reassuring under stricter fill-focused grading.

GBBS reads like a launch-stage vendor, not a long-running supplier. A Utah LLC filing, privacy-protected NameCheap domain, Reddit vendor account, WordPress build activity, and first Finnrick tests all land inside a compressed early-2026 window. The public Utah address resolves to registered-agent and process-service infrastructure, and the founder story gives exercise-science and GIS background without a legal name.

The storefront evidence is similarly immature. The shop was captured in a coming-soon state, homepage vials named NAD, Retatrutide, and GHK-CU before the report found independent testing for those products, and the Terms and Conditions path led to a placeholder. The operator’s Reddit comments are unusually candid about gray-market status and China sourcing; candor helps, but it does not replace lot-level verification or buyer recourse.

For buyers, the directional read is peptide-specific: GBBS is a plausible BPC-157 candidate only if the current lot is verified and fill shortfall is accounted for. It is not yet supported for the implied broader catalog. The scan found no public sister-site cluster, paid promoter network, Trustpilot/BBB history, or mature complaint record; with a new storefront, absence of reviews mostly means absence of time.

Inside the full report:

  • Launch timeline tying the LLC filing, domain registration, Reddit account, WordPress build, and first Finnrick tests.
  • BPC-157 lab analysis, sample-source caveat, fill-accuracy issue, and methodology-divergence charts.
  • Registered-agent address evidence from the GBBS contact page, InCorp Services, and Beehive Attorney Service records.
  • Founder-profile and Reddit-source review, including gray-market and China-sourcing statements.
  • Infrastructure, payment, affiliate, sister-site, and external-reputation sweeps with dead ends, open leads, and the buyer risk matrix.

Risk assessment

  • Unverified catalog risk — high: NAD, Retatrutide, GHK-CU, and any products beyond BPC-157 have no independent test coverage; current safety record supports BPC-157 only.
  • BPC-157 fill-accuracy risk — medium: Both BPC-157 vials tested from batch 000001 passed but contained 7.8% and 12.2% less than the 5 mg label claim.
  • BPC-157 testing-independence risk — medium: All current Finnrick data comes from vendor-submitted Launch with Finnrick samples; no independently purchased market sample has been tested.
  • Consumer-contract risk — medium: The Terms and Conditions page was a launch placeholder, leaving disputes, returns, and liability largely undefined.
  • Ownership-accountability risk — medium: No named operator appears in public filings, WHOIS, or the website; only biographical founder details are available.
  • Operating-location opacity risk — medium: The published Utah address resolves to InCorp Services/Beehive Attorney Service; no storage, fulfillment, or lab address was found.